文献速递妇科产科

IOTA ADNEX模型在中国妇科肿瘤中心评估附件肿块的性能

Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
PubMed 文献 · Ultrasound Obstet Gynecol · 2019-11-11

本研究为单中心回顾性诊断准确性研究,基于2017年5月至12月前瞻性收集的278例附件肿块患者超声数据,评估IOTA ADNEX模型术前诊断准确性。模型区分良恶性肿块AUC为0.94(含CA 125)和0.93(不含CA 125),含CA 125时区分不同肿瘤类型AUC在0.61至0.99之间。作者认为ADNEX模型在中国背景下有良好至优秀性能,对临床术前诊断有帮助。

要点

  • ADNEX模型区分良恶性附件肿块AUC为0.94(含CA 125)和0.93(不含CA 125),P=0.54。
  • 含CA 125模型区分良性卵巢肿瘤与II-IV期卵巢癌AUC为0.99(95%CI 0.97-1.00)。
  • 含CA 125模型区分交界性卵巢肿瘤与I期卵巢癌AUC为0.61(95%CI 0.43-0.77)。

核心结论

  • IOTA ADNEX模型在中国背景下区分良恶性附件肿块及不同卵巢肿瘤类型显示良好至优秀性能。
  • 作者认为ADNEX模型在临床实践中有高价值,可辅助附件肿块患者的术前诊断。

研究设计与样本

  • 单中心、回顾性诊断准确性研究,基于2017年5月至12月前瞻性收集的超声数据。
  • 纳入278例至少有一个附件(卵巢、卵巢旁或输卵管)肿块的患者,均接受手术,以组织病理学诊断为参考标准。
  • 收集临床和病理信息、血清CA 125水平及超声表现,按ADNEX模型分为五类肿瘤类型。
  • 采用受试者工作特征(ROC)曲线分析评估ADNEX模型诊断准确性,分别评估含与不含CA 125水平。

主要发现

  • 278例中良性卵巢肿瘤203例(73.0%),恶性卵巢肿瘤75例(27.0%)。
  • 恶性卵巢肿瘤中交界性卵巢肿瘤18例(6.5%),I期卵巢癌17例(6.1%),II-IV期卵巢癌32例(11.5%),卵巢转移8例(2.9%)。
  • 含CA 125时区分良恶性AUC为0.94(95%CI 0.91-0.97),不含CA 125时AUC为0.93(95%CI 0.90-0.96)。
  • 含CA 125模型区分不同肿瘤类型AUC在0.61至0.99之间,区分良性卵巢肿瘤与II-IV期卵巢癌AUC为0.99(95%CI 0.97-1.00)。
  • 含CA 125模型区分交界性卵巢肿瘤与I期卵巢癌AUC为0.61(95%CI 0.43-0.77),区分II-IV期卵巢癌与卵巢转移AUC为0.78(95%CI 0.62-0.90)。

关键数值与推荐

  • 含与不含CA 125区分良恶性病变的AUC分别为0.94和0.93,P=0.54,差异无统计学显著。
  • 含CA 125较不含CA 125区分I期卵巢癌与II-IV期卵巢癌的AUC从0.81升至0.92,P=0.04。
  • 含CA 125较不含CA 125区分II-IV期卵巢癌与转移癌的AUC从0.58升至0.78,P=0.01。

临床怎么用

  • 作者认为ADNEX模型在临床实践中有高价值,可辅助附件肿块患者的术前诊断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the diagnostic accuracy of the International Ovarian Tumor Analysis (IOTA) Assessment of Different NEoplasias in the adneXa (ADNEX) model in the preoperative diagnosis of adnexal masses using data from a gynecological oncology center in China. METHODS: This was a single-center, retrospective diagnostic accuracy study based on ultrasound data collected prospectively, between May and December 2017, from 278 patients with at least one adnexal (ovarian, paraovarian or tubal) mass. Clinical and pathologic information, serum CA 125 level and ultrasonographic findings were collected. All patients underwent surgery and the histopathological diagnosis was used as reference standard. The final diagnosis was classified into five tumor types according to the ADNEX model: benign ovarian tumor, borderline ovarian tumor (BOT), Stage-I ovarian cancer (OC), Stages-II-IV OC and ovarian metastasis. Receiver-operating characteristics (ROC) curve analysis was used to evaluate the diagnostic accuracy of the ADNEX model, with and without inclusion of CA 125 level in the model. RESULTS: Of the 278 women included, 203 (73.0%) had a benign ovarian tumor and 75 (27.0%) had a malignant ovarian tumor, including 18 (6.5%) with BOT, 17 (6.1%) with Stage-I OC, 32 (11.5%) with Stages-II-IV OC and eight (2.9%) with ovarian metastasis. The performance of the IOTA ADNEX model was good for discriminating between benign and malignant tumors, with an area under the ROC curve (AUC) of 0.94 (95% CI, 0.91-0.97) when CA 125 was included in the model and AUC of 0.93 (95% CI, 0.90-0.96) without CA 125. The AUC values of the model including CA 125 ranged between 0.61 and 0.99 for distinguishing between the different types of tumor, and it showed excellent performance in discriminating between a benign ovarian tumor and Stages-II-IV OC, with an AUC of 0.99 (95% CI, 0.97-1.00). The performance of the model was less effective at distinguishing between BOT and Stage-I OC and between Stages-II-IV OC and ovarian metastasis, with AUC values of 0.61 (95% CI, 0.43-0.77) and 0.78 (95% CI, 0.62-0.90), respectively. Although inclusion of CA 125 did not alter the performance of the ADNEX model in discriminating between benign and malignant lesions (AUC of 0.94 and 0.93 with and without CA 125 level, respectively; P = 0.54), the inclusion of CA 125 in the model improved its performance in discriminating between Stage-I OC and Stages-II-IV OC (AUC increased from 0.81 to 0.92; P = 0.04) and between Stages-II-IV OC and metastatic cancer (AUC increased from 0.58 to 0.78; P = 0.01). CONCLUSIONS: The IOTA ADNEX model showed good to excellent performance in distinguishing between benign and malignant adnexal masses and between the different types of ovarian tumor in a Chinese setting. Based on our findings, the ADNEX model has high value in clinical practice and can aid in the preoperative diagnosis of patients with an adnexal mass. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chen H, Qian L, Jiang M, et al. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China. Ultrasound Obstet Gynecol. 2019. PMID: 31152572. doi:10.1002/uog.20363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。